Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
Tacrolimus for Thrombocytopenia in SS
- Conditions
- Sjogren Syndrome With Other Organ Involvement
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05678335
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fen Li
- Target Recruit Count
- 30
- Registration Number
- NCT05666336
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China
The Clinical Features and Pregnancy Outcomes of RA Patients
- Conditions
- Pregnancy RelatedRheumatoid Arthritis
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT05651373
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
- Conditions
- GemcitabineLung NeoplasmsHydroxychloroquine
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05647330
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
- Conditions
- Antiphospholipid Syndrome
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 80
- Registration Number
- NCT05644210
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
The Clinical Efficacy of Immunomodulators in RA Patients
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 400
- Registration Number
- NCT05626348
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
- Conditions
- Stage IV Colorectal Cancer Positive for BRAF V600E MutationColorectal CancerColorectal Cancer Stage IV
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 43
- Registration Number
- NCT05576896
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 22
- Registration Number
- NCT05518110
- Locations
- 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪St Vincent's University Hospital, Dublin, Ireland
Safety and Efficacy of Enoxaparin and Hydroxychloroquine in COVID-19
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 200
- Registration Number
- NCT05311813
- Locations
- 🇪🇬
Beni-Suef University teaching Hospital, Banī Suwayf, Cairo, Egypt
The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Yoo-min Kim
- Target Recruit Count
- 58
- Registration Number
- NCT05287321
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.